Hepatitis C virus chronicity and oncogenic potential: Vaccine development progress

Area of Science:

• Hepatology
• Virology
• Immunology
• Vaccinology

Background:

• Hepatitis C virus (HCV) infection is a global health concern, leading to liver cirrhosis and hepatocellular carcinoma (HCC).
• Direct-acting antiviral agents (DAAs) have improved HCV treatment outcomes but do not eliminate HCC risk in advanced liver disease or induce lasting immunity, leaving patients susceptible to reinfection.

Purpose of the Study:

• To review the current understanding of HCV's impact on liver disease and cancer progression.
• To examine the immune responses involved in HCV infection and host evasion mechanisms.
• To discuss current strategies and challenges in developing a prophylactic HCV vaccine.

Main Methods:

• Literature review of scientific publications on Hepatitis C virus.
• Analysis of immunological data concerning host-pathogen interactions.
• Synthesis of information on current vaccine development approaches for HCV.

Main Results:

• HCV infection poses significant risks for liver disease progression and HCC development.
• DAAs offer therapeutic benefits but do not confer protective immunity against reinfection or fully mitigate HCC risk.
• HCV employs immune evasion strategies, complicating vaccine-induced immunity.

Conclusions:

• A prophylactic HCV vaccine is essential for comprehensive HCV control, aiming to induce robust humoral and cellular immunity.
• Overcoming HCV's immune evasion mechanisms is critical for successful vaccine development.
• Advancing prophylactic strategies is key to preventing HCV chronicity, liver disease, and HCC.